Quantcast

Latest NS5 Stories

2011-04-02 01:00:00

RIDGEFIELD, Conn., April 2, 2011 /PRNewswire/ -- Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most challenging genotype to treat. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development programs for BI...

2011-04-01 09:00:00

BERLIN and RIDGEFIELD, Conn., April 1, 2011 /PRNewswire/ -- New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat. Results from SILEN-C1 show a sustained viral response (SVR)...

2011-02-10 05:59:00

HUDDINGE, Sweden, February 10, 2011 /PRNewswire/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase 1a clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus infection. TMC649128 is a nucleoside NS5B polymerase inhibitor that has already demonstrated an attractive pre-clinical profile. It is anticipated that this profile would see TMC649128 be used...

2011-01-05 07:00:00

BRISBANE, Calif., Jan. 5, 2011 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2011, at 4:30 p.m. EST / 1:30 p.m. PST. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at...

2010-10-30 08:00:00

BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load below the lower limit of quantifiable levels in HCV treatment-naive patients. The regimen did not include interferon through the first 28 days of...

2010-04-13 06:30:00

PRINCETON, N.J., April 13 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the oral presentation of new sustained virologic response (SVR) follow-up data in hepatitis C virus (HCV) genotype 2 and 3 non-responder patients treated for 28 days with RG7128 in combination with the standard of care (SOC), Pegasys® and Copegus®, and presentation of an in vitro combination study with PSI-7977 and PSI-938. Both presentations are at the 45th...

2010-03-02 08:30:00

WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing. "Our NS5A inhibitor program is well positioned to generate a pipeline of clinical candidates, and we are excited about further...

2010-03-02 08:30:00

ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott. Each antiviral agent...

2009-12-02 17:26:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities http://www.reportlinker.com/p0164272/Hepatitis-C-Virus-And-Therapeutics---A-Global-Update-of-Market-Trends--Opportunities.html Bucking the trend witnessed for all these years of meager clinical outcomes owing to lack of superior therapies, research & development in...

2009-10-16 09:17:00

NEW YORK, Oct. 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Competitor Analysis: Targeted Therapy of Hepatitis C http://www.reportlinker.com/p0154666/Reportlinker-Adds-Competitor-Analysis-Targeted-Therapy-of-Hepatitis-C.html Product description The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.